Evidence map›Paper›PMID 42319383›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026

Reconsidering Surgical Strategy in the Era of Neoadjuvant Immunotherapy for Head and Neck Cancer.

Andrea Migliorelli, Andrea Sacchetto, Snehal Patel

Abstract read
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrea MigliorelliENT & Audiology Unit, Department of Neurosciences, University Hospital of Ferrara, Ferrara, Italy.ORCID https://orcid.org/0009-0004-8980-3877
Andrea SacchettoUnit of Otorhinolaryngology, Specialized Surgery Department, San Bortolo Hospital, Vicenza, ULSS8, Italy.
Snehal PatelHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant immunotherapy is increasingly incorporated into the management of resectable locally advanced mucosal head and neck squamous cell carcinoma, raising questions about its impact on surgical decision-making. Despite encouraging trial data, limitations in response assessment and evidence of heterogeneous tumor regression challenge the use of treatment response to guide surgical de-escalation. This commentary highlights current uncertainties and emphasizes the need for prospective evidence before response-adapted surgical strategies can be safely implemented.

Indexed as

Head and Neck NeoplasmsImmunotherapyNeoadjuvant TherapySquamous Cell Carcinoma of Head and NeckHumanshead and neck neoplasmsimmunotherapyneoadjuvant therapysurgical procedures

Identifiers

PMID42319383
PMCPMC13525881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.